dc.contributor.author | Meini, Simone et al. | |
dc.date.accessioned | 2020-07-27T21:59:02Z | |
dc.date.available | 2020-07-27T21:59:02Z | |
dc.date.issued | 2020-06-30 | |
dc.identifier.uri | https://doi.org/10.3390/jcm9072050 | en_US |
dc.identifier.uri | https://hdl.handle.net/20.500.12663/2094 | |
dc.description.abstract | A life-threatening respiratory illness (COVID-19) due to severe acute respiratory syndrome (SARS)-CoV-2 coronavirus was first described in December 2019 in Wuhan (China), rapidly evolving into a pandemic. In the first phase, when the viral replication plays a pivotal pathogenetic role, antiviral drugs could be crucial in limiting viral-induced organ damage. Unfortunately, there are no specific antivirals of proven efficacy for COVID-19, and several drugs have been repurposed to face this dramatic pandemic. In this paper we review the studies evaluating lopinavir/ritonavir association (LPV/r) use in COVID-19, and previously in SARS and Middle East respiratory syndrome (MERS). We searched PubMed to identify all relevant clinical and laboratory studies published up to 15 May 2020; the guidelines on the use of LPV/r in COVID-19 were further directly searched on the website of the main international scientific societies and agencies. Available evidence is currently scarce and of low quality. The recommendations issued for COVID-19 vary from positions clearly against the use of LPV/r to other positions that are more favorable. In our opinion, despite the controversial results of an important randomized clinical trial, and some recommendations, clinicians should not abandon the use of LPV/r for the treatment of COVID-19, possibly using this drug inside a prospective randomized trial, waiting for the results of the numerous ongoing trials evaluating its efficacy. | en_US |
dc.language | English | en_US |
dc.subject | COVID-19 | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | Coronavirus Infections | en_US |
dc.subject | Infectious Diseases | en_US |
dc.subject | Lopinavir | en_US |
dc.subject | Ritonavir | en_US |
dc.subject | Severe Acute Respiratory Syndrome | en_US |
dc.subject | Middle East Respiratory Syndrome Coronavirus | en_US |
dc.subject | Guideline | en_US |
dc.subject | Health Planning Guidelines | en_US |
dc.title | Role of Lopinavir/Ritonavir in the Treatment of Covid-19: A Review of Current Evidence, Guideline Recommendations, and Perspectives | en_US |
eihealth.country | Others | en_US |
eihealth.category | Candidate therapeutics RD | en_US |
eihealth.type | Published Article | en_US |
eihealth.maincategory | Save Lives / Salvar Vidas | en_US |
dc.relation.ispartofjournal | Journal of Clinical Medicine | en_US |